Art. 1 Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009…

Definitions

In forcesince 1 Jul 2019cited 45×

For the purposes of this Regulation, the following definitions shall apply:

(a)

‘medicinal product’ means any substance or combination of substances presented for treating or preventing disease in human beings or animals and any substance or combination of substances which may be administered to human beings or animals with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in humans or in animals;

(b)

‘product’ means the active ingredient or combination of active ingredients of a medicinal product;

(c)

‘basic patent’ means a patent which protects a product as such, a process to obtain a product or an application of a product, and which is designated by its holder for the purpose of the procedure for grant of a certificate;

(d)

‘certificate’ means the supplementary protection certificate;

(e)

‘application for an extension of the duration’ means an application for an extension of the duration of the certificate pursuant to Article 13(3) of this Regulation and Article 36 of Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use [OJ L 378, 27.12.2006, p. 1.];

(f)

‘maker’ means the person, established in the Union, on whose behalf the making of a product, or a medicinal product containing that product, for the purpose of export to third countries or for the purpose of storing, is carried out.

The 10 that are cited most themselves, of 45.

  • Judgment of the Court (Fourth Chamber) of 24 November 2011. Medeva BV v Comptroller General of Patents, Designs and Trade Marks.Decision

    Article 1 of Regulation No 469/2009, headed ‘Definitions’, provides as follows: ‘For the purposes of this Regulation, the following definitions shall apply: (a) “medicinal product” means any substance or combination of substances …

    24 Nov 2011 · 62010CJ0322

  • Judgment of the Court (Fourth Chamber) of 24 November 2011. Georgetown University and Others v Comptroller General of Patents, Designs and TDecision

    Article 1 of Regulation No 469/2009, headed ‘Definitions’, provides as follows: ‘For the purposes of this Regulation, the following definitions shall apply: “medicinal product” means any substance or combination of substances …

    24 Nov 2011 · 62010CJ0422

  • Judgment of the Court (Eighth Chamber) of 15 January 2015. Arne Forsgren v Österreichisches Patentamt.Decision

    По изложените съображения Съдът (осми състав) реши: 1) Член 1, буква б) и член 3, буква a) от Регламент (ЕО) № 469/2009 на Европейския …

    15 Jan 2015 · 62013CJ0631

  • Judgment of the Court (Fourth Chamber), 19 July 2012. Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents.Decision

    Article 1 of the regulation provides: ‘Definitions For the purposes of this Regulation, the following definitions shall apply: “medicinal product” means any substance or combination of substances presented for treating or preventing …

    19 Jul 2012 · 62011CJ0130

  • Order of the Court (Fourth Chamber) of 25 November 2011. University of Queensland and CSL Ltd v Comptroller General of Patents, Designs and Decision

    Article 1 of Regulation No 469/2009, headed ‘Definitions’, provides as follows: ‘For the purposes of this Regulation, the following definitions shall apply: (a) “medicinal product” means any substance or combination of substances …

    25 Nov 2011 · 62010CO0630

  • Order of the Court (Fourth Chamber) of 25 November 2011. Daiichi Sankyo Company v Comptroller General of Patents, Designs and Trade Marks.Decision

    Article 1 of Regulation No 469/2009, headed ‘Definitions’, provides as follows: ‘For the purposes of this Regulation, the following definitions shall apply: “medicinal product” means any substance or combination of substances …

    25 Nov 2011 · 62011CO0006

  • Judgment of the Court (Third Chamber), 12 December 2013. Actavis Group PTC EHF and Actavis UK Ltd v Sanofi.Decision

    It is true that the Court has held, in a situation in which a ‘product’ within the meaning of Article 1 of Regulation No 469/2009 is protected by a number of basic patents in force, which may belong to different patent holders and may …

    12 Dec 2013 · 62012CJ0443

  • Judgment of the Court (Third Chamber), 12 December 2013. Eli Lilly and Company Ltd v Human Genome Sciences Inc.Decision

    Article 1 of Regulation No 469/2009, headed ‘Definitions’, provides as follows: ‘For the purposes of this Regulation, the following definitions shall apply: (a) “medicinal product” means any substance or combination of substances …

    12 Dec 2013 · 62012CJ0493

  • Judgment of the Court (Grand Chamber) of 25 July 2018. Teva UK Ltd and Others v Gilead Sciences Inc.Decision

    Article 1 of that regulation provides: ‘For the purposes of this Regulation, the following definitions shall apply: “medicinal product” means any substance or combination of substances presented for treating or preventing disease in …

    25 Jul 2018 · 62017CJ0121

  • Order of the Court (Eighth Chamber), 14 November 2013. Glaxosmithkline Biologicals SA and Glaxosmithkline Biologicals, Niederlassung der SmiDecision

    Article 1 of Regulation No 469/2009, headed ‘Definitions’, provides as follows: ‘For the purposes of this Regulation, the following definitions shall apply: “medicinal products” means any substance or combination of substances …

    14 Nov 2013 · 62013CO0210